RSS Atom • ISSN 1472-4683 • Subscribe • About
Antiretrovirals
- Similar efficacy and a few gender related differences in side effects with rilpivirine vs efavirenz at 96-weeks Antiretrovirals - Conference reports - PMTCT and maternal health - Intl Workshop on HIV and Women 2nd 2011 - 1 February 2012
- The effect of BMI on efficacy, safety and tolerability of lopinavir/r in women Antiretrovirals - Conference reports - Women's health - 1 February 2012
- Poorer adherence and loss to follow up in Kenyan women who are pregnant when enrolled to ART programmes Antiretrovirals - Conference reports - PMTCT and maternal health - Intl Workshop on HIV and Women 2nd 2011 - 1 February 2012
- Nevirapine prolonged release (PR) once-daily formulation available in the UK Antiretrovirals - 1 February 2012
- Efavirenz dose increase to 800 mg QD with rifampin in patients >50 kg Antiretrovirals - 1 February 2012
- Raltegravir achieves superiority over efavirenz after four years Antiretrovirals - Conference reports - EACS 13 Belgrade 2011 - 1 December 2011
- Statin blocks negative impact of PIs on bone formation in vitro Antiretrovirals - Conference reports - HIV and Ageing Baltimore 2011 - 1 December 2011
- Intracellular raltegravir concentrations better with twice-daily than once-daily dosing Antiretrovirals - Conference reports - ICAAC 51th Chicago 2011 - 1 December 2011
- Rilpivirine (Edurant) and rilpivirine/FTC/tenofovir FDC (Eviplera) approved in Europe Antiretrovirals - 1 December 2011
- Lopinavir concentrations suboptimal at reduced dose of lopinavir/ritonavir 200/50 mg twice daily Antiretrovirals - PK and drug interactions - 1 December 2011
- Switching to 50mg ritonavir dose for selected protease inhibitors Antiretrovirals - PK and drug interactions - 1 December 2011
- US guidelines (DHHS) update recommendations for first-line combinations (October 2011) Antiretrovirals - 1 December 2011
- Fixed-dose combination of rilpivirine/tenofovir/FTC (Eviplera) recommended for approval in Europe Antiretrovirals - 1 October 2011
- Treatment is prevention: ARV treatment in HPTN-052 reduces transmission by at least 96%: single transmission in treatment arm occurred prior to viral suppression Antiretrovirals - Conference reports - Transmission and prevention - IAS 6 Rome 2011 - 1 August 2011
- Daily oral tenofovir/FTC PrEP reduces heterosexual transmission by 63% in the TDF2 study Antiretrovirals - Conference reports - Transmission and prevention - IAS 6 Rome 2011 - 1 August 2011
- Tenofovir/FTC vs tenofovir as daily oral PrEP: preliminary results from Partners PrEP Antiretrovirals - Conference reports - Transmission and prevention - IAS 6 Rome 2011 - 1 August 2011
- Elvitegravir vs raltegravir: 48 week results in treatment-experienced patients Antiretrovirals - Conference reports - IAS 6 Rome 2011 - 1 August 2011
- Dolutegravir: 48 week results from phase II study in treatment-naïve patients Antiretrovirals - Conference reports - IAS 6 Rome 2011 - 1 August 2011
- Lersivirine: 48 week results compared to efavirenz in phase 2 treatment-naïve study Antiretrovirals - Conference reports - IAS 6 Rome 2011 - 1 August 2011
- Maraviroc plus atazanavir/r without nukes versus standard of care: 48 week results Antiretrovirals - Conference reports - IAS 6 Rome 2011 - 1 August 2011
- SPARTAC trial: treatment in primary infection for 48 weeks shows small delay in disease progression Antiretrovirals - Conference reports - 1 August 2011
- Paediatric antiretroviral pipeline: darunavir and raltegravir Antiretrovirals - Conference reports - Paediatric care - CROI 18 (Retrovirus) 2011 - 1 August 2011
- FDA approve new NNRTI-based fixed dose combination of rilpivirine/tenofovir/FTC (Complera) in the US Antiretrovirals - 1 August 2011
- Atazanavir in pregnancy: 155 cases in London clinics Antiretrovirals - Conference reports - PMTCT and maternal health - Women's health - BHIVA 17th Bournmouth 2011 - 1 May 2011
- Quad reduces levels of oral contraceptives Antiretrovirals - Conference reports - PK and drug interactions - PK Workshop 12th 2011 - 1 May 2011
- Elvitegravir/cobicistat and acid reducing agents Antiretrovirals - Conference reports - PK and drug interactions - PK Workshop 12th 2011 - 1 May 2011
- Lopinavir/r reduces levels of rifabutin Antiretrovirals - Conference reports - PK and drug interactions - PK Workshop 12th 2011 - 1 May 2011
- Cobicistat has little impact on CYP2D6 and CYP2B6 Antiretrovirals - Conference reports - PK Workshop 12th 2011 - 1 May 2011
- Atazanavir levels indicate need for higher dose during pregnancy Antiretrovirals - Conference reports - PMTCT and maternal health - PK Workshop 12th 2011 - 1 May 2011
- Etravirine lowers levels of maraviroc given at 300 or 600 mg twice daily Antiretrovirals - Conference reports - PK Workshop 12th 2011 - 1 May 2011
- Once-daily 150-mg maraviroc explored in people taking atazanavir/ritonavir Antiretrovirals - Conference reports - PK Workshop 12th 2011 - 1 May 2011
- Lopinavir troughs lower in children on once-daily dose with efavirenz Antiretrovirals - Conference reports - Paediatric care - PK Workshop 12th 2011 - 1 May 2011
- Dose optimisation: 50 mg ritonavir-boosting, 3TC dosing and raltegravir once-daily Antiretrovirals - Conference reports - Treatment strategies - PK Workshop 12th 2011 - 1 May 2011
- Rapid report: state of HCV policy, treatment, access Antiretrovirals - Conference reports - EASL 48 2011 - 1 May 2011
- When to start ART in patients co-infected with TB: results from two trials presented at CROI Antiretrovirals - Conference reports - TB coinfection - CROI 18 (Retrovirus) 2011 - 1 May 2011
- Inflammation and intervention: how does HIV cause AIDS and how does it cause disease despite ART Antiretrovirals - Conference reports - CROI 18 (Retrovirus) 2011 - 1 May 2011
- New antiretrovirals: dolutegravir, entry inhibitor (BMS-663068) and tenofovir pro-drug (GS-7340) Antiretrovirals - Conference reports - CROI 18 (Retrovirus) 2011 - 1 April 2011
- Immune-based treatment increases HIV-resistant CD4 cells in phase 1 study Antiretrovirals - Conference reports - CROI 18 (Retrovirus) 2011 - 1 April 2011
- Antiretroviral prevention: oral PrEP, gels and treatment studies Antiretrovirals - Conference reports - CROI 18 (Retrovirus) 2011 - 1 April 2011
- Further efficacy analyses from the iPrEx study Antiretrovirals - Conference reports - CROI 18 (Retrovirus) 2011 - 1 April 2011
- Topical gels as PEP and PrEP: animal and human studies Antiretrovirals - Conference reports - CROI 18 (Retrovirus) 2011 - 1 April 2011
- Maternal risk following short course HAART Antiretrovirals - Conference reports - PMTCT and maternal health - CROI 18 (Retrovirus) 2011 - 1 April 2011
- Pre-term delivery and HAART Antiretrovirals - Conference reports - PMTCT and maternal health - CROI 18 (Retrovirus) 2011 - 1 April 2011
- HAART more effective than AZT monotherapy in the Botswana PMTCT programme Antiretrovirals - Conference reports - PMTCT and maternal health - CROI 18 (Retrovirus) 2011 - 1 April 2011
- Lopinavir/r monotherapy for PMTCT Antiretrovirals - Conference reports - PMTCT and maternal health - CROI 18 (Retrovirus) 2011 - 1 April 2011
- First results from telaprevir in HIV/HCV coinfection Antiretrovirals - Conference reports - Hepatitis coinfection - CROI 18 (Retrovirus) 2011 - 1 April 2011
- London HIV Consortium issues new guidelines for ARV prescribing Antiretrovirals - Guidelines - 1 April 2011
- Lopinavir/ritonavir: women versus men Antiretrovirals - Conference reports - Women's health - Intl Workshop on HIV and Women 1st 2011 - 1 February 2011
- Quality of life in the GRACE study Antiretrovirals - Conference reports - Women's health - Intl Workshop on HIV and Women 1st 2011 - 1 February 2011
- Antiretroviral pharmacokinetics in women with undetectable viral load Antiretrovirals - Conference reports - Women's health - Intl Workshop on HIV and Women 1st 2011 - 1 February 2011
- No association between bone mineral density and lipodystrophy in women receiving antiretroviral therapy Antiretrovirals - Conference reports - Lipodystrophy and metabolic complications - Women's health - Intl Workshop on HIV and Women 1st 2011 - 1 February 2011
- The impact of antiretroviral treatment on fertility intentions in South Africa Antiretrovirals - Conference reports - PMTCT and maternal health - Women's health - Intl Workshop on HIV and Women 1st 2011 - 1 February 2011
- Virological findings from the SARA trial of boosted protease inhibitor monotherapy Antiretrovirals - Conference reports - Treatment access - Virology - HIV 10 Glasgow 2010 - 1 December 2010
- Nevirapine exposure was not associated with hypersensitivity in patients from Malawi Antiretrovirals - Conference reports - Side effects - HIV 10 Glasgow 2010 - 1 December 2010
- Estimating the number of people in a country or region with HIV who are undiagnosed and in need of ART Antiretrovirals - Conference reports - HIV 10 Glasgow 2010 - 1 December 2010
- Efavirenz versus nevirapine based first line treatment in a South African cohort Antiretrovirals - Conference reports - PMTCT and maternal health - HIV 10 Glasgow 2010 - 1 December 2010
- GSK572: 24-week results in treatment-naïve and raltegravir-experienced patients Antiretrovirals - Conference reports - HIV 10 Glasgow 2010 - 1 December 2010
- Consensus guidelines recommend routine use of genotypic tropism testing: new focus on maraviroc as a switching option Antiretrovirals - Conference reports - Guidelines - HIV 10 Glasgow 2010 - 1 December 2010
- Muscle weakness or pain analysed as possible raltegravir side effect Antiretrovirals - Conference reports - Side effects - HIV 10 Glasgow 2010 - 1 December 2010
- Adding maraviroc does not boost CD4s in randomised trial Antiretrovirals - Conference reports - HIV 10 Glasgow 2010 - 1 December 2010
- Switch to twice-daily unboosted atazanavir outdoes switch to once-daily dose Antiretrovirals - Conference reports - HIV 10 Glasgow 2010 - 1 December 2010
- Small but higher rates of AIDS and non-AIDS complications with uncontrolled HIV despite CD4s over 350 Antiretrovirals - Conference reports - HIV 10 Glasgow 2010 - 1 December 2010
- Once-daily raltegravir fails to demonstrate non-inferiority compared to twice-daily dosing in phase 3 treatment naïve study Antiretrovirals - 1 December 2010
- Raltegravir pharmacokinetics in pregnancy Antiretrovirals - Conference reports - PMTCT and maternal health - ICAAC 50th Boston 2010 - 1 October 2010
- Low birth weight associated with HAART in pregnancy in Zambia Antiretrovirals - Conference reports - PMTCT and maternal health - ICAAC 50th Boston 2010 - 1 October 2010
- Bilirubin levels in infants following in utero atazanavir exposure compared to exposure to other antiretrovirals Antiretrovirals - Conference reports - PMTCT and maternal health - ICAAC 50th Boston 2010 - 1 October 2010
- Novel mutations and shifting susceptibility to darunavir and tipranavir Antiretrovirals - Conference reports - Resistance - ICAAC 50th Boston 2010 - 1 October 2010
- Four-drug single-pill antiretroviral equivalent to Atripla at 48 weeks Antiretrovirals - Conference reports - ICAAC 50th Boston 2010 - 1 October 2010
- High rates of bone loss and progression with HIV in longitudinal study Antiretrovirals - Conference reports - Side effects - ICAAC 50th Boston 2010 - 1 October 2010
- Spray-dried nanoparticle formulation of efavirenz Antiretrovirals - Conference reports - World AIDS 18 Vienna 2010 - 1 October 2010
- Switching boosted-PIs to raltegravir Antiretrovirals - Conference reports - Treatment strategies - World AIDS 18 Vienna 2010 - 1 October 2010
- Early infant diagnosis Antiretrovirals - Conference reports - Diagnostics - Paediatric care - World AIDS 18 Vienna 2010 - 1 October 2010
- Efavirenz-based regimens among women of reproductive age receiving ART in Johannesburg Antiretrovirals - Conference reports - PMTCT and maternal health - Women's health - World AIDS 18 Vienna 2010 - 1 October 2010
- Saquinavir prolongation of QT interval: Roche issue Dear Doctor letter Antiretrovirals - 1 October 2010
- Development of chronic kidney disease and antiretroviral use in EuroSIDA cohort since 2004 Antiretrovirals - Side effects - 1 October 2010
- Rilpivirine (TMC-278) vs efavirenz in treatment-naïve patients: phase 3 results Antiretrovirals - Conference reports - World AIDS 18 Vienna 2010 - 26 August 2010